LEO Pharma’s Adtralza approved by MHRA, EC for adolescent atopic dermatitis
Adbry, adolescent treatment, atopic dermatitis, EC, LEO Pharma, MHRA, tralokinumab
0 Comment
EC
EC to update IP rules to benefit generic exports
biosimilar, biosimilars Europe, EC, EU, European Commission, European pharma, generics, pharma IP, Pharma regulation
0 Comment
The European Commission (EC) is proposing to adjust intellectual property (IP) rules to help Europe’s pharma companies tap into fast-growing global markets.
Clinical trial lay summaries: a clearer picture emerges
clinical trial data, clinical trial lay summaries, clinical trials, EC, EU, lay summary, patient centricity, patients
0 Comment
EC wants pharma to make clinical trial results more patient-friendly.